Christian Cortes

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

M. Ammirati, A. Carlo, A. Mathiowetz, 2015, ACS medicinal chemistry letters.

PF-1355, a Mechanism-Based Myeloperoxidase Inhibitor, Prevents Immune Complex Vasculitis and Anti–Glomerular Basement Membrane Glomerulonephritis

A. Kalgutkar, T. Maurer, L. Buckbinder, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Endothelial protein kinase MAP 4 K 4 promotes vascular inflammation and atherosclerosis Citation

L. Buckbinder, M. Czech, R. Flach, 2015 .

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

M. Ammirati, L. Buckbinder, A. El‐Kattan, 2018, Journal of medicinal chemistry.

Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis

L. Buckbinder, M. Czech, M. Aouadi, 2015, Nature Communications.

Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition

A. Kalgutkar, L. Buckbinder, E. Keliher, 2019, PloS one.

Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

John W. Chen, Y. Iwamoto, L. Buckbinder, 2016, JACC. Basic to translational science.

Endothelial protein kinase MAP4K4 promotes vascular Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis inflammation and atherosclerosis Let us know how access to this document benefits you.

S. Bhattacharya, L. Buckbinder, M. Czech, 2022 .